Bone Metastasis Medical Services in China

Bone metastasis refers to the spread of malignant tumor cells from a primary cancer site—most commonly breast, prostate, lung, thyroid, or kidney—to bone tissue. It is not a primary bone cancer but rather a systemic manifestation of advanced malignancy, often presenting with severe pain, pathological fractures, spinal cord compression, or hypercalcemia. Diagnosis typically involves whole-body bone scintigraphy, PET-CT, MRI, and biopsy confirmation. Management is multidisciplinary, integrating systemic therapies (e.g., bisphosphonates, denosumab, targeted agents), radiation oncology (including stereotactic body radiotherapy), orthopedic interventions (e.g., cementoplasty, internal fixation, tumor resection with reconstruction), and palliative care. Early detection and individualized treatment significantly improve quality of life and skeletal-related event-free survival.

China offers distinct advantages for international patients seeking bone metastasis care. Leading tertiary hospitals—such as Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—house nationally accredited oncology and orthopedic oncology units with extensive experience in complex metastatic bone disease. Advanced technologies—including intraoperative navigation, real-time 3D imaging, robotic-assisted surgery, and high-precision radiotherapy platforms—are widely deployed. Clinical outcomes reflect this capability: published data show >85% local control rates after SBRT for spinal metastases and >90% implant survival at 2 years following endoprosthetic reconstruction. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities). As a dedicated medical tourism agency, we facilitate seamless access: coordinating specialist consultations, arranging hospital admissions, providing transparent itemized pricing, assisting with visas and travel logistics, and offering bilingual clinical support throughout the care journey.

Treatment Options & Itemized Cost Breakdown: Bone Metastases (Orthopedic Oncology)

Non-Surgical / Conservative / Medication Options

*Indicated for stable lesions, low tumor burden, or patients unfit for surgery.*

• •Bisphosphonates (e.g., Zoledronic Acid): IV infusion every 3–4 weeks.

- Pre-infusion renal function panel (creatinine, eGFR, electrolytes): $45 - Monitoring LFTs/Ca²⁺/P at each cycle: $35/cycle

• •Denosumab (subcutaneous): Monthly injection.

- Baseline dental exam (mandated): $65

• •Systemic Therapy (Chemotherapy/Targeted/Immunotherapy): Managed by oncology; orthopedic coordination only.

- MRI spine/pelvis (for neural compression assessment): $280–$350

Surgical / Procedural / Interventional Options

*Eligibility: Pathologic fracture risk (Mirels’ score ≥8), impending or actual fracture, spinal cord compression, or mechanical instability.*

• •Percutaneous Vertebroplasty/Kyphoplasty (1 level):

- Pre-op: Spine MRI + CT angiogram (vascular mapping): $410

• •Stabilization Surgery (e.g., Intramedullary nailing, Plate fixation):

- Spinal fusion (3–5 levels, posterior approach): $7,200–$9,500 - Pre-op: Full spine CT + pulmonary function test + cardiac echo (if >65 yrs or comorbid): $520

• •En Bloc Resection (rare, high-grade metastases with solitary lesion):

- Pre-op: PET-CT + multidisciplinary tumor board review fee: $680

Special / Complex Condition Options

• •Spinal Cord Compression (urgent): Emergency decompression + stabilization within 24h.

• •Multiple Myeloma–associated lytic lesions: High-dose dexamethasone + bortezomib + orthopedic bracing.

• •Radiotherapy–resistant lesions with progressive pain: Radiopharmaceuticals (¹⁷⁷Lu-PSMA or ²²³Ra-chloride).

Quick Selection Guide

• •Elderly (>75), frail, multiple comorbidities: Start with denosumab + kyphoplasty ($420–$2,700) — avoids major anesthesia.
• •Working-age adult, single-site femoral metastasis, Mirels’ score 9: Intramedullary nailing ($3,800) — definitive mechanical stabilization.
• •Budget-constrained (<$1,000 total): Zoledronic acid + palliative RT planning MRI ($180 + $280 = $460) + outpatient analgesia.
• •Spinal cord compression + ambulatory: Urgent decompression/fusion ($8,400) — neurologic preservation is cost-effective vs. permanent paralysis.
• •Solitary, radioresistant, non–small cell lung cancer origin: En bloc resection + adjuvant immunotherapy ($12,500 + oncology costs) — potential cure in select cases.